by Ethan Perlstein | Jun 14, 2018 | Rare Diseases |
I just attended the 2018 Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C (NPC) research. My mind is still spinning from all the productive interactions and conversations I had over three session-packed days at The Westin La Paloma...
by Ethan Perlstein | Jun 4, 2018 | Organic Intelligence, Science |
What is the role of OI in drug discovery? Organic Intelligence (OI) is the collective brainpower and high emotional quotient of scientists and rare disease advocates teaming up to use the PerlArk™ Platform of model organisms, lab automation and computation for a new...
by Ethan Perlstein | Apr 6, 2018 | MSD |
I’m excited to share the latest news! Today we announced our sixth PerlQuest partnership. Our PerlQuest partner is the Multiple Sulfatase Deficiency Action Foundation (MSDAF), a research-focused charity based in Ireland whose mission is to work towards a cure for...
by Ethan Perlstein | Mar 13, 2018 | Business |
Economies of scale are the efficiencies unlocked by large numbers. I’ve come to realize that the efficiencies of scale can emerge at the opposite extreme of rare – especially ultra-rare – genetic disease communities, which can number as few as dozens to thousands of...
by Ethan Perlstein | Feb 26, 2018 | Business |
Today is Perlara’s birthday — 4 years old! As the first biotech public benefit corporation (bioPBC) we embraced openness in business and science from the start. As part of that commitment to accountability, I’m pleased to share our 2017 Benefit...
